Rapacuronium bromide
Clinical data
  • US: C (Risk not ruled out)
Routes of
ATC code none
Legal status
Legal status
  • Withdrawn (U.S)
Pharmacokinetic data
Bioavailability Not applicable
Protein binding Variable
Metabolism Hydrolyzed to active metabolites
CYP system not involved
Biological half-life 141 minutes (mean)
Excretion Renal and fecal
Synonyms [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate
CAS Number 156137-99-4 N
PubChem (CID) 5311398
DrugBank DB04834 YesY
ChemSpider 4470889 YesY
ECHA InfoCard 100.211.226
Chemical and physical data
Formula C37H61N2O4+
Molar mass 597.891 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Rapacuronium (Raplon) is a rapidly acting, non-depolarizing neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.

Due to risk of fatal bronchospasm it was withdrawn from the United States market by Organon on March 27, 2001, less than 2 years after its FDA approval in 1999.[1]


  1. Shapse, Deborah (March 27, 2001). "Voluntary Market Withdrawal" (PDF). (10.8 KiB). Organon International. Retrieved on 2007-04-02.
This article is issued from Wikipedia - version of the 11/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.